Latest news
Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor Debio 0932 – Study to test Debio…
Debiopharm Group™ – First patient treated in Phase III study with subcutaneous administration of Debio 8206 for treatment of advanced…
Debiopharm Group is investing in Tweasy, the Saas e-marketing platform for SMEs
Debiopharm, Immunexpress and Biocartis Announce Collaboration to Advance Development of SeptiCyte® Triage for Managing Sepsis
Debiopharm and Ascepion Pharmaceuticals, Inc. announce an exclusive license agreement for the development and commercialisation of the dual-targeting kinase Inhibitor,…
Debiopharm Presented Results at the ASCO 2012 Annual meeting – Results of Phase I study with Debio 0932, an oral…
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…
Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…